Ondine Biomedical

Ondine Biomedical Inc., a Canadian life sciences company established in 1999, is focused on developing and commercializing photodisinfection-based therapies to combat a wide range of infections, including those resistant to antimicrobials. The company was founded by Carolyn Cross, who currently serves as the Chief Executive Officer. Ms. Cross has over 30 years of experience with public market securities and over 25 years working with early-stage companies, holding a background as a Chartered Financial Analyst (CFA) and a former Vice President at Royal Bank Investment Management Inc.

The company's core business revolves around its patented platform technology, Photodisinfection, also known as antimicrobial photodynamic therapy (aPDT). This technology employs a photosensitive agent that is activated by a non-thermal laser light, creating an oxidative reaction that destroys pathogens like bacteria, viruses, and fungi within minutes without harming human tissue or generating microbial resistance. Ondine's primary source of revenue is through the sale of its antimicrobial photodynamic therapy (aPDT) products. The company's revenue reached C$2.05 million in 2024, a 70.32% increase from the previous year, driven by a rise in hospital deployments.

Ondine's flagship product is Steriwave™, a nasal decolonization therapy designed to eliminate pathogens in the nasal passages that can lead to healthcare-associated infections (HAIs). This rapid, five-minute treatment has been shown to reduce surgical site infection rates by up to 84% in Canadian hospitals where it has been used for over a decade. Steriwave has received a CE mark for use in Europe and the UK and is also approved in Canada and Mexico. The company is actively pursuing FDA approval in the United States, with its technology granted Fast Track status. A strategic partnership with Mölnlycke Health Care aims to expand Steriwave's distribution into key international markets. Beyond nasal decolonization, Ondine's product pipeline includes treatments for chronic rhinosinusitis, burns and wounds, and the prevention of ventilator-associated pneumonia.

Keywords: photodisinfection, antimicrobial therapies, anti-infective, medical devices, healthcare-associated infections, surgical site infections, antimicrobial resistance, aPDT, Steriwave, nasal decolonization, pathogen eradication, life sciences, therapeutic devices, non-antibiotic treatment, light-activated therapies, infection control, hospital-acquired infections, MRSA, Carolyn Cross, medical technology